spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Astellas Pharma US 

 HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Biopharmaceuticals Urology Oncology Regulatory
 HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Feb 2016
Astellas Names James Robinson President, Americas Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2014
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Biopharmaceuticals Distribution
 HSMN NewsFeed - 24 May 2013
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2011
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 2 Nov 2010
Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2009
Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL(TM) DosePro(TM) Needle-Free Delivery System
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 3 Aug 2009
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2009
Astellas Announces New Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2009
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Astellas to Terminate Offer for CV Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Feb 2009
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Feb 2009
Astellas Pharma Issues Statement Regarding CV Therapeutics Rejection of All-Cash Proposal
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Jan 2009
Astellas Proposes to Acquire CV Therapeutics for $16 per Share in Cash
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Aug 2008
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 24 Jun 2008
Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
Biopharmaceuticals Radiology Cardiology
 HSMN NewsFeed - 15 Apr 2008
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2008
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jan 2008
Cardiome And Astellas Announce Regulatory Update
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2007
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2007
Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2007
Adenoscan(R) Patent Lawsuits Settled
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 22 Oct 2007
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2007
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2007
CV Therapeutics Submits New Drug Application For Regadenoson
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 30 Apr 2007
Cardiome Announces In-Licensing Agreement With Eli Lilly and Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Mar 2007
Cardiome Announces Appointment of Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2007
Cardiome Announces Management Appointments
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 20 Feb 2007
Theravance Announces FDA Acceptance of Telavancin NDA
Biopharmaceuticals
 HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Biopharmaceuticals
 HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2006
Advanced Life Sciences Announces Election of Theron (Ted) E. Odlaug, Ph.D. to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2006
Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Sep 2006
Cardiome Announces USAN Name And Patent Grant
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Aug 2006
Theravance Announces Positive Results in Phase 3 Telavancin Complicated Skin and Skin Structure Infection Program
Biopharmaceuticals
 HSMN NewsFeed - 14 Aug 2006
Astellas Pharma US, Inc. Selects Dendrite for Sample Compliance Solutions
Biopharmaceuticals
 HSMN NewsFeed - 26 Jul 2006
Phase III Study Demonstrates Once-a-Day Prograf MR(TM) (Modified Release) and Twice-Daily Prograf(R) Are as Effective as Neoral(R) in Kidney Transplant Recipients
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2006
Study Demonstrates Improved Renal Function and Lipid Values in Kidney Transplant Patients on Prograf(R) Compared to Patients Taking Neoral(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2006
Adolor Corporation Appoints Scott T. Megaffin as Vice President, Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jun 2006
CV Therapeutics Completes Enrollment of Second Regadenoson Phase 3 Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 May 2006
Cardiome Announces Refusal To File Decision By The FDA
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 16 May 2006
Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program With Investigational Antibiotic, Telavancin
Biopharmaceuticals
 HSMN NewsFeed - 3 Apr 2006
Astellas to Acquire AMEVIVE(R) (alefacept)
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 31 Mar 2006
Astellas Receives FDA Approval of Prograf(R) (Tacrolimus) for Use in Heart Transplant Recipients
Biopharmaceuticcals FDA
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Astellas Pharma US
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.